Gaining Stereoselectivity in Asymmetric Synthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gaining Stereoselectivity in Asymmetric Synthesis
Researchers use inorganic catalysts as an alternative to biocatalysts in the selective conversion of sugars to produce chiral building blocks.


Pharmaceutical Technology
Volume 37, Issue 2

References

1. Y. Román-Leshkov, "Sn-Beta Zeolites with Borate Salts Catalyze the Epimerization of Carbohydrates via an Intramolecular Carbon Shift," Nature Comnun., online, DOI:10.1038/ncomms2122, Oct. 9, 2012.

2. I. Shiina, J. Med Chem. 56 (1), 150–159 (2013).

3. J. Zhou, "Organocatalytic Asymmetric Synthesis of 3,3-Disubstituted Oxindoles Featuring Two Heteroatoms at C3 position," Chem. Commun., online, DOI: 10.1039/C3CC38819K, Jan. 23, 2013.

4. A.D. Lim, J.A. Codelli, and S.E. Reisman, "Catalytic Asymmetric Synthesis of Highly Substituted Pyrrolizidines," Chem. Sci., online, DOI: 10.1039/C2SC21617E, Nov. 13, 2012.

5. M.J. Abrahamson, Angew. Chem., Int. Ed. Engl., 51 (16), 3969–3972 (2012).

6. G. Sahoo, Angew. Chem., Int. Ed. Engl. 51 (52), 13144–13148 (2012).

7. W. Sommer and D. Weibel, Aldrich ChemFiles 8.2 (56) (2008).

8. D.H. Paull, J. Am. Chem. Soc., 134 (27), 11128–11131 (2012).

9. C. Drahl, Chem. & Eng. News 90 (28), 29 (2012).

Patricia Van Arnum is executive editor of Pharmaceutical Technology, 485 Route One South, Bldg F, First Floor, Iselin, NJ 08830 tel. 732.346.3072,
twitter@PharmTechVArnum


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here